Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular non-Hodgkin’s lymphoma who had achieved a partial response or a complete response after receiving one of the standard first-line chemotherapy regimens. This treatment was found to significantly increase progression free survival. Prof Hagenbeek explains how the Zevalin radioimmunotherapy targets and kills the lymphoma cells, outlines the toxicity profile associated with this treatment and discusses the benefits of this treatment in relation to other antibody therapies.